Purpose of this Study
We are doing this study to find out if anti-HER2 treatment can be safely stopped in patients with metastatic HER2+ breast cancer who have had an exceptional response to treatment for at least 3 years.
Who Can Participate?
Eligibility
Adults ages 18+ who:
- Are diagnosed with metastatic HER2+ breast cancer
- Have been on first-line anti-HER2 therapy for at least 3 years
- Have not had any disease progression
For more information about who can join this study, please contact the study team at breastcl@dm.duke.edu.
- Are diagnosed with metastatic HER2+ breast cancer
- Have been on first-line anti-HER2 therapy for at least 3 years
- Have not had any disease progression
For more information about who can join this study, please contact the study team at breastcl@dm.duke.edu.
What is Involved?
If you choose to join this study, you will:
- Make a choice to participate in 1 of 2 groups
-- You can continue to receive the anti-HER2 therapy you are taking; OR
-- You can stop taking anti-HER2 therapy
- Have blood draws
- Have imaging scans
- Complete questionnaires
- Give us permission to use your stored tissue samples
- Make a choice to participate in 1 of 2 groups
-- You can continue to receive the anti-HER2 therapy you are taking; OR
-- You can stop taking anti-HER2 therapy
- Have blood draws
- Have imaging scans
- Complete questionnaires
- Give us permission to use your stored tissue samples
Study Details
Full Title
A Phase 2 Study of Stopping Trastuzumab - Outcomes in
Patients with HER2+ Metastatic Breast Cancer
Patients with HER2+ Metastatic Breast Cancer
Principal Investigator
Kelly
Westbrook
Protocol Number
PRO00113523
NCT ID
NCT05721248
Phase
II
Enrollment Status
Open to Enrollment